John D. Hart, Alma Fulurija, Tria Williams, Hannah Frost, Ciara Baker, Elizabeth Negus, Maria Angel, Jasmyn Voss, Anna Takahashi, Natalie Caltabiano, Kaneka Chheng, Michael Morici, Angela D'Aprile, Isabel Lester, Adriana Messineo, Taylor Mills, Katharine Noonan, Matthew G. Parnaby, Chantalia Tedja, Serene Yeow, Andrew C. Steer
{"title":"A prospective cohort study of Streptococcus pyogenes sore throat among Australian children: preparation for future vaccine trials","authors":"John D. Hart, Alma Fulurija, Tria Williams, Hannah Frost, Ciara Baker, Elizabeth Negus, Maria Angel, Jasmyn Voss, Anna Takahashi, Natalie Caltabiano, Kaneka Chheng, Michael Morici, Angela D'Aprile, Isabel Lester, Adriana Messineo, Taylor Mills, Katharine Noonan, Matthew G. Parnaby, Chantalia Tedja, Serene Yeow, Andrew C. Steer","doi":"10.1016/j.lanwpc.2026.102007","DOIUrl":"10.1016/j.lanwpc.2026.102007","url":null,"abstract":"<div><h3>Background</h3><div><em>Streptococcus pyogenes</em> causes a spectrum of illness from acute sore throat to acute rheumatic fever and rheumatic heart disease, a major burden in resource-limited settings. With <em>S. pyogenes</em> vaccine candidates advancing, prospective community-based epidemiological data are needed to inform efficacy trial design.</div></div><div><em>Streptococcus pyogenes</em> causes a spectrum of illness from acute sore throat to acute rheumatic fever and rheumatic heart disease, a major burden in resource-limited settings. With <em>S. pyogenes</em> vaccine candidates advancing, prospective community-based epidemiological data are needed to inform efficacy trial design.</div><div><h3>Methods</h3><div>A prospective, community-based cohort study was conducted in Melbourne and Perth, Australia from July 2021 to July 2023. Children aged 3–14 years were recruited and followed for 12 months, with physical, microbiological and immunological assessments at baseline, two scheduled timepoints, and at any acute sore throat episodes. Primary outcomes were 12-month cumulative incidence of first all cause sore throat, first culture-positive <em>S. pyogenes</em> sore throat, first serology-positive <em>S. pyogenes</em> sore throat, and prevalence of asymptomatic <em>S. pyogenes</em> carriage at scheduled timepoints. Kaplan–Meier methods were used to analyse cumulative incidence. We also assessed the incidence rate of all episodes, expressed per 100 person-years, using Poisson regression. Analyses were conducted overall and by prespecified subgroups.</div></div><div>A prospective, community-based cohort study was conducted in Melbourne and Perth, Australia from July 2021 to July 2023. Children aged 3–14 years were recruited and followed for 12 months, with physical, microbiological and immunological assessments at baseline, two scheduled timepoints, and at any acute sore throat episodes. Primary outcomes were 12-month cumulative incidence of first all cause sore throat, first culture-positive <em>S. pyogenes</em> sore throat, first serology-positive <em>S. pyogenes</em> sore throat, and prevalence of asymptomatic <em>S. pyogenes</em> carriage at scheduled timepoints. Kaplan–Meier methods were used to analyse cumulative incidence. We also assessed the incidence rate of all episodes, expressed per 100 person-years, using Poisson regression. Analyses were conducted overall and by prespecified subgroups.</div><div><h3>Findings</h3><div>During the 12-month follow-up of 503 enrolled children, there were 370 sore throat episodes among 212 children and 88 <em>S. pyogenes</em> sore throat episodes among 74 children. Annual cumulative incidence of sore throat was 43.1% (95% CI: 38.8–47.7), <em>S. pyogenes</em> sore throat was 15.2% (95% CI: 12.3–18.7), and serology-positive <em>S. pyogenes</em> sore throat was 10.6% (95% CI: 8.2–13.7). Age-specific cumulative incidence of <em>S. pyogenes</em> sore throat was 14.6% (95% CI: 9.1–23.1) among chi","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"76 ","pages":"Article 102007"},"PeriodicalIF":9.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149375432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ratu Atonio Rabici Lalabalavu, Sandro Demaio, Mark Jacobs, Elizabeth Bennett, Saia Ma’u Piukala
{"title":"When global climate diplomacy comes to the Pacific, health must be at the table","authors":"Ratu Atonio Rabici Lalabalavu, Sandro Demaio, Mark Jacobs, Elizabeth Bennett, Saia Ma’u Piukala","doi":"10.1016/j.lanwpc.2026.102003","DOIUrl":"10.1016/j.lanwpc.2026.102003","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"75 ","pages":"Article 102003"},"PeriodicalIF":9.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13730220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149324848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dongkyu Lee, In-Hwan Oh, John S. Ji, Mikiko Kanda, Hitomi Kimura, Siwon Lee, Josselyn Mothe, Jinah Park, Enkhtsetseg Shinee, Ho Kim
{"title":"Age-stratified health impacts of climate change on older adults in the Western Pacific Region: a scoping review","authors":"Dongkyu Lee, In-Hwan Oh, John S. Ji, Mikiko Kanda, Hitomi Kimura, Siwon Lee, Josselyn Mothe, Jinah Park, Enkhtsetseg Shinee, Ho Kim","doi":"10.1016/j.lanwpc.2026.102004","DOIUrl":"10.1016/j.lanwpc.2026.102004","url":null,"abstract":"<div><div>While research on the health impacts of climate change is growing, studies integrating these effects across finer age strata within older adult populations, such as distinguishing young-old from old–old adults remain scarce, particularly in the Western Pacific region. This scoping review synthesizes 119 cases extracted from 100 peer-reviewed studies published from 2016 to 2025, identified via systematic searches of PubMed, Scopus, and Embase using keyword clusters for older adults, climate change, and the Western Pacific. Most cases (n = 61, 51%) examined heat, followed by extreme cold (n = 31, 26%), air pollution (n = 11, 9%), with geographic concentration in mainland China (n = 84, 71%); old–old adults generally showed greater vulnerability than young-old adults. These findings suggest heterogeneity in climate impacts among older adults, indicating that a one-size-fits-all approach may be insufficient and that finer age stratifications could help inform policies better tailored to old–old adults.</div></div><div>While research on the health impacts of climate change is growing, studies integrating these effects across finer age strata within older adult populations, such as distinguishing young-old from old–old adults remain scarce, particularly in the Western Pacific region. This scoping review synthesizes 119 cases extracted from 100 peer-reviewed studies published from 2016 to 2025, identified via systematic searches of PubMed, Scopus, and Embase using keyword clusters for older adults, climate change, and the Western Pacific. Most cases (n = 61, 51%) examined heat, followed by extreme cold (n = 31, 26%), air pollution (n = 11, 9%), with geographic concentration in mainland China (n = 84, 71%); old–old adults generally showed greater vulnerability than young-old adults. These findings suggest heterogeneity in climate impacts among older adults, indicating that a one-size-fits-all approach may be insufficient and that finer age stratifications could help inform policies better tailored to old–old adults.</div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"75 ","pages":"Article 102004"},"PeriodicalIF":9.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149254095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Spatiotemporal trajectories of antimicrobial resistance in bloodstream infections in China: a nationwide longitudinal surveillance study from 2014 to 2023","authors":"Yunbo Chen, Zhiying Liu, Jinru Ji, Chaoqun Ying, Hua Zhang, Haisheng Kong, Qing Yang, Ping Shen, Yonghong Xiao","doi":"10.1016/j.lanwpc.2026.102010","DOIUrl":"10.1016/j.lanwpc.2026.102010","url":null,"abstract":"<div><h3>Background</h3><div>Bloodstream infections (BSIs) impose a substantial global burden, increasingly complicated by antimicrobial resistance (AMR). We aimed to characterise decade-long trends in BSI pathogens and major resistance phenotypes across mainland China.</div></div><div>Bloodstream infections (BSIs) impose a substantial global burden, increasingly complicated by antimicrobial resistance (AMR). We aimed to characterise decade-long trends in BSI pathogens and major resistance phenotypes across mainland China.</div><div><h3>Methods</h3><div>We analysed BSI surveillance data from 72 hospitals across 22 provinces in the Bacterial Resistant Investigation Collaborative System (BRICS) between 2014 and 2023. Isolates were transferred to a central reference laboratory for species identification and standardised antimicrobial susceptibility testing, with raw minimum inhibitory concentration values retrospectively reinterpreted using 2025 CLSI guidelines. Fourteen continuously participating hospitals formed a sentinel cohort.</div></div><div>We analysed BSI surveillance data from 72 hospitals across 22 provinces in the Bacterial Resistant Investigation Collaborative System (BRICS) between 2014 and 2023. Isolates were transferred to a central reference laboratory for species identification and standardised antimicrobial susceptibility testing, with raw minimum inhibitory concentration values retrospectively reinterpreted using 2025 CLSI guidelines. Fourteen continuously participating hospitals formed a sentinel cohort.</div><div><h3>Findings</h3><div>Among 76,211 non-duplicate BSI isolates, <em>Escherichia coli</em> and <em>Klebsiella pneumoniae</em> predominated, with <em>K. pneumoniae</em> increasing by 0.91 percentage points annually (95% CI 0.59–1.23; <em>p</em> < 0.001). Extended-spectrum β-lactamase (ESBL)-producing <em>E. coli</em> decreased from 61.5% to 47.4%, MRSA from 39.0% to 26.2%, and ESBL-producing <em>K. pneumoniae</em> from 30.5% to 21.5% (all <em>p</em> < 0.001). Conversely, carbapenem-resistant <em>K. pneumoniae</em> increased from 7.0% to 14.9%, peaking at 22.5% in 2018, with marked spatial heterogeneity. CRAB remained persistently high (55.2–64.3%). Resistance proportions were higher in intensive care units, older patients and male patients for several phenotypes.</div></div><div>Among 76,211 non-duplicate BSI isolates, <em>Escherichia coli</em> and <em>Klebsiella pneumoniae</em> predominated, with <em>K. pneumoniae</em> increasing by 0.91 percentage points annually (95% CI 0.59–1.23; <em>p</em> < 0.001). Extended-spectrum β-lactamase (ESBL)-producing <em>E. coli</em> decreased from 61.5% to 47.4%, MRSA from 39.0% to 26.2%, and ESBL-producing <em>K. pneumoniae</em> from 30.5% to 21.5% (all <em>p</em> < 0.001). Conversely, carbapenem-resistant <em>K. pneumoniae</em> increased from 7.0% to 14.9%, peaking at 22.5% in 2018, with marked spatial heterogeneity. CRAB remained persistently high (55.2–64.3%). Resistance ","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"75 ","pages":"Article 102010"},"PeriodicalIF":9.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149253946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"“Indigenous models of social prescribing”–a six-domain framework for social wellbeing and other support services delivered by Aboriginal Community Controlled Health Organisations","authors":"Uday Narayan Yadav, Chelsea Liu, Reece Griffin, Rosemary Wyber, Isabel Hanson, Odette Pearson","doi":"10.1016/j.lanwpc.2026.101999","DOIUrl":"10.1016/j.lanwpc.2026.101999","url":null,"abstract":"<div><div>This viewpoint examines the literature to illuminate the role of Aboriginal community-controlled health organisations in supporting access to social wellbeing and other support services that address the social and cultural determinants of health and wellbeing for Aboriginal and Torres Strait Islander peoples. Our papers call on primary care providers, researchers, and policymakers to apply and test the six-domain framework we developed to describe their engagement with social wellbeing and other support services, and to showcase their work, control, and financial needs.</div></div><div>This viewpoint examines the literature to illuminate the role of Aboriginal community-controlled health organisations in supporting access to social wellbeing and other support services that address the social and cultural determinants of health and wellbeing for Aboriginal and Torres Strait Islander peoples. Our papers call on primary care providers, researchers, and policymakers to apply and test the six-domain framework we developed to describe their engagement with social wellbeing and other support services, and to showcase their work, control, and financial needs.</div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"75 ","pages":"Article 101999"},"PeriodicalIF":9.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149202700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Franco Wing Tak Cheng, Jiayi Gong, Andrew Tomlin, William Harrison, Kebede Beyene, Helen K. Reddel, Jeff Harrison, Mark Hew, Amy Hai Yan Chan
{"title":"Implementation of the National Asthma Guidelines in New Zealand: a retrospective patient-level study of the change to anti-inflammatory reliever therapy in 324,972 patients","authors":"Franco Wing Tak Cheng, Jiayi Gong, Andrew Tomlin, William Harrison, Kebede Beyene, Helen K. Reddel, Jeff Harrison, Mark Hew, Amy Hai Yan Chan","doi":"10.1016/j.lanwpc.2026.102002","DOIUrl":"10.1016/j.lanwpc.2026.102002","url":null,"abstract":"<div><h3>Background</h3><div>The updated New Zealand asthma guidelines in 2020, aligning with global asthma guideline recommendations, advocated for a fundamental shift from short-acting β2-agonist (SABA) reliever therapy to anti-inflammatory reliever (AIR) therapy (ICS-formoterol) in adults and adolescents. While aggregate population-level data indicate increased ICS-formoterol dispensings, patient-level changes in medication use remain unclear. We examined medication use patterns to assess early practice changes across the entire asthma population.</div></div><div>The updated New Zealand asthma guidelines in 2020, aligning with global asthma guideline recommendations, advocated for a fundamental shift from short-acting β2-agonist (SABA) reliever therapy to anti-inflammatory reliever (AIR) therapy (ICS-formoterol) in adults and adolescents. While aggregate population-level data indicate increased ICS-formoterol dispensings, patient-level changes in medication use remain unclear. We examined medication use patterns to assess early practice changes across the entire asthma population.</div><div><h3>Methods</h3><div>We conducted a retrospective study using the New Zealand national linked health datasets. Patients aged ≥12 with asthma were identified from hospitalisation and/or dispensing data, and categorised by the complete set of inhaler classes dispensed in the three months preceding their final dispensing date within the baseline (July 2018–June 2020) and post-guideline (June 2020–June 2022) periods. Nine mutually exclusive categories were defined without applying any hierarchy between medications: SABA only; ICS, non-formoterol ICS-LABA, and ICS-formoterol, each with and without a concurrently dispensed SABA; other regimens; and no inhaled medication. Age subgroups (12–44 and ≥ 45 years) were examined. Children aged < 12 years throughout follow-up, who were outside the scope of the recommendation, served as a comparison cohort for difference-in-differences estimation.</div></div><div>We conducted a retrospective study using the New Zealand national linked health datasets. Patients aged ≥12 with asthma were identified from hospitalisation and/or dispensing data, and categorised by the complete set of inhaler classes dispensed in the three months preceding their final dispensing date within the baseline (July 2018–June 2020) and post-guideline (June 2020–June 2022) periods. Nine mutually exclusive categories were defined without applying any hierarchy between medications: SABA only; ICS, non-formoterol ICS-LABA, and ICS-formoterol, each with and without a concurrently dispensed SABA; other regimens; and no inhaled medication. Age subgroups (12–44 and ≥ 45 years) were examined. Children aged < 12 years throughout follow-up, who were outside the scope of the recommendation, served as a comparison cohort for difference-in-differences estimation.</div><div><h3>Findings</h3><div>The cohort included 324,972 patients aged ≥12 years. At baseline, ","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"75 ","pages":"Article 102002"},"PeriodicalIF":9.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149254096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Accelerating the Western Pacific tobacco endgame","authors":"The Lancet Regional Health – Western Pacific","doi":"10.1016/j.lanwpc.2026.102018","DOIUrl":"10.1016/j.lanwpc.2026.102018","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"75 ","pages":"Article 102018"},"PeriodicalIF":9.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13730221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149324845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}